ACAD Overview

Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Wall Street analysts forecast ACAD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACAD is31.17 USD with a low forecast of 23.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

ACADIA Pharmaceuticals Inc revenue for the last quarter amounts to 268.06M USD, increased 9.72

ACADIA Pharmaceuticals Inc. EPS for the last quarter amounts to 0.02 USD, decreased -81.82

ACADIA Pharmaceuticals Inc (ACAD) has 796 emplpoyees as of July 08 2026.

Today ACAD has the market capitalization of 4.49B USD.